Prestige floats $100 mil. note for Blacksmith buy
This article was originally published in The Tan Sheet
Executive Summary
Prestige Brands sells $100 million worth of debt to help finance its acquisition of Blacksmith Brands. The senior notes the firm announced Oct. 22 will have the same terms as the 8.25 percent notes the company issued in March and are due in 2018. Prestige Sept. 20 announced its $190 million acquisition of year-old Blacksmith, which markets brands including denture products Efferdent and Effergrip, cough and cold products PediaCare and Luden's and allergy drug NasalCrom (1"The Tan Sheet" Sept. 27, 2010)
You may also be interested in...
Prestige Brands Makes "Seismic Shift" To OTC With Blacksmith Acquisition
On the eve of Blacksmith Brands' one-year anniversary, co-founder and CEO Peter Mann fulfills his promise to cash in on the startup in a $190 million sale to Prestige Brands Holdings, which Mann also helped launch
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.